Journal Mobile Options
Table of Contents
Vol. 86, No. 3, 2011
Issue release date: April 2011
Urol Int 2011;86:284–289
(DOI:10.1159/000322645)

Long-Term Efficacy of Serenoa repens Treatment in Patients with Mild and Moderate Symptomatic Benign Prostatic Hyperplasia

Sinescu I. · Geavlete P. · Multescu R. · Gangu C. · Miclea F. · Coman I. · Ioiart I. · Ambert V. · Constantin T. · Petrut B. · Feciche B.
To view the fulltext, log in and/or choose pay-per-view option

Individual Users: Register with Karger Login Information

Please create your User ID & Password





Contact Information











I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in

Abstract

Introduction: The study aimed to evaluate the long-term efficacy of treatment with extract of Serenoa repens (Prostamol Uno) in patients with lower urinary tract symptoms (LUTS) induced by benign prostatic hyperplasia (BPH). Patients and Methods: We studied 120 patients with mild or moderate LUTS induced by BPH, maximal urinary flow (Qmax) <15 ml with a voided volume ≧150 ml, prostate-specific antigen <4 ng/ml, and residual urinary volume <150 ml, treated daily for 24 months with one capsule of 320 mg ethanolic extract of Serenoa repens. Results: Statistically significant improvements in the International Prostate Symptom Score (5.5 points), quality of life (QoL; 1.8 points), Qmax (5.6 ml/s), International Index of Erectile Function (IIEF; 6.4 points) and reduction in residual urinary volume were observed during the study period. The mean prostate volume at 24 months was 36 ml, compared to 39.8 ml at baseline. Conclusions: Long-term treatment with 320 mg ethanolic extract of Serenoa repens proved to be efficient in reducing urinary obstruction, improving symptomatology and QoL of BPH patients. It also had a positive effect on sexual function, demonstrated by the statistically significant increase in the IIEF.



Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

References

  1. Andersen JT, Nickel JC, Marshall VR, Schulman CC, Boyle P: Finasteride significantly reduces acute urinary retention and need for surgery in patients with symptomatic benign prostatic hyperplasia. Urology 1997;49:839–845.
  2. Debruyne F, Boyle P, Calais Da Silva F, Gillenwater JG, Hamdy FC, Perrin P, Teillac P, Vela-Navarrete R, Raynaud JP, Schulman CC: Evaluation of the clinical benefit of permixon and tamsulosin in severe BPH patients – PERMAL study subset analysis. Eur Urol 2004;45:773–779.
  3. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 1996;29:231–240, discussion 241–242.
  4. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD: Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001;58:960–964, discussion 964–965.
  5. Marks LS, Partin AW, Epstein JI, Tyler VE, Simon I, Macairan ML, Chan TL, Dorey FJ, Garris JB, Veltri RW, Santos PB, Stonebrook KA, deKernion JB: Effects of a saw palmetto herbal blend in men with symptomatic benign prostatic hyperplasia. J Urol 2000;163:1451–1456.
  6. Bauer HW, Casarosa C, Cosci M, Fratta M, Blessmann G: Saw palmetto fruit extract for treatment of benign prostatic hyperplasia. Results of a placebo-controlled double-blind study (in German). MMW Fortschr Med 1999;141:62.
  7. Giannakopoulos X, Baltogiannis D, Giannakis D, Tasos A, Sofikitis N, Charalabopoulos K, Evangelou A: The lipidosterolic extract of Serenoa repens in the treatment of benign prostatic hyperplasia: a comparison of two dosage regimens. Adv Ther 2002;19:285–296.
  8. Tacklind J, MacDonald R, Rutks I, Wilt TJ: Serenoa repens for benign prostatic hyperplasia. Cochrane Database Syst Rev 2009;15:CD001423.
  9. Willetts KE, Clements MS, Champion S, Ehsman S, Eden JA: Serenoa repens extract for benign prostate hyperplasia: a randomized controlled trial. BJU Int 2003;92:267–270.
  10. Descotes JL, Rambeaud JJ, Deschaseau P, et al: Placebo-controlled evaluation of the efficacy and tolerability of Permixon in benign prostatic hyperplasia after exclusion of placebo responders. Clin Drug Invest 1995;9:291–297.

    External Resources

  11. Gerber GS, Zagaja GP, Bales GT, Chodak GW, Contreras BA: Saw palmetto (Serenoa repens) in men with lower urinary tract symptoms: effects on urodynamic parameters and voiding symptoms. Urology 1998;51:1003–1007.
  12. Pytel YA, Vinarov A, Lopatkin N, Sivkov A, Gorilovsky L, Raynaud JP: Long-term clinical and biologic effects of the lipidosterolic extract of Serenoa repens in patients with symptomatic benign prostatic hyperplasia. Adv Ther 2002;19:297–306.
  13. Gerber GS, Kuznetsov D, Johnson BC, Burstein JD: Randomized, double-blind, placebo-controlled trial of saw palmetto in men with lower urinary tract symptoms. Urology 2001;58:960–964.
  14. Habib FK, Wyllie MG. Not all brands are created equal: a comparison of selected components of different brands of Serenoa repens extract. Prostate Cancer Prostatic Dis 2004;7:195–200.
  15. Scaglione F, Lucini V, Pannacci M, Caronno A, Leone C: Comparison of the potency of different brands of Serenoa repens extract on 5alpha-reductase types I and II in prostatic co-cultured epithelial and fibroblast cells. Pharmacology 2008;82:270–275.
  16. Breza J, Kliment J, Valansky L, Capova G: Phytotherapy of symptomatic benign prostatic hyperplasia using alcohol extract of Serenoa repens fruit (Prostamol Uno). Urologia 2005;11:6–10.
  17. Alyaev YG, Apolikhin OI, Mazo EB, Vinarov AZ, Lokshin KL, Medvedev AA, Permyakova OV, Spivak LG, Shkol’nikov ME: First results of a clinical trial of the efficacy and safety of Prostamol® Uno in patients with the early signs of prostatic hyperplasia. Eff Pharmacother Urol 2007;11:8–11.
  18. Vinarov AZ, Aliaev IuG, Lokshin KL: Safety of continuous (more than 1 year) intake of Serenoa repens extract by patients with prostatic adenoma (in Russian). Urologiia 2009;1:84, 86–87.
  19. Agbabiaka TB, Pittler MH, Wider B, Ernst E: Serenoa repens (saw palmetto): a systematic review of adverse events. Drug Saf 2009;32:637–647.
  20. Avins AL, Bent S, Staccone S, Badua E, Padula A, Goldberg H, Neuhaus J, Hudes E, Shinohara K, Kane C: A detailed safety assessment of a saw palmetto extract. Complement Ther Med 2008;16:147–154.
  21. Giuliano F: Impact of medical treatments for benign prostatic hyperplasia on sexual function. BJU Int 2006;97(suppl 2):34–38, discussion 44–45.
  22. Zlotta AR, Teillac P, Raynaud JP, Schulman CC: Evaluation of male sexual function in patients with lower urinary tract symptoms (LUTS) associated with benign prostatic hyperplasia (BPH) treated with a phytotherapeutic agent (Permixon), Tamsulosin or Finasteride. Eur Urol 2005;48:269–276.
  23. Bent S, Kane C, Shinohara K, Neuhaus J, Hudes ES, Goldberg H, Avins AL: Saw palmetto for benign prostatic hyperplasia. N Engl J Med 2006;354:557–566.
  24. Hizli F, Uygur MC: A prospective study of the efficacy of Serenoa repens, tamsulosin, and Serenoa repens plus tamsulosin treatment for patients with benign prostate hyperplasia. Int Urol Nephrol 2007;39:879–886.


Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50